Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?

  • Ruiz Molina, Daniel
  • Mao, Xiaoman
  • Alfonso Triguero, Paula
  • Lorenzo, Julia
  • Bruna, Jordi
  • Yuste, Víctor J.
  • Candiota, Ana Paula
  • Novio, Fernando
Glioblastoma multiforme (GB) is the most aggressive and frequent primary malignant tumor in the central nervous system (CNS), with unsatisfactory and challenging treatment nowadays. Current standard of care includes surgical resection followed by chemotherapy and radiotherapy. However, these treatments do not much improve the overall survival of GB patients, which is still below two years (the 5-year survival rate is below 7%). Despite various approaches having been followed to increase the release of anticancer drugs into the brain, few of them demonstrated a significant success, as the blood brain barrier (BBB) still restricts its uptake, thus limiting the therapeutic options. Therefore, enormous efforts are being devoted to the development of novel nanomedicines with the ability to cross the BBB and specifically target the cancer cells. In this context, the use of nanoparticles represents a promising non-invasive route, allowing to evade BBB and reducing systemic concentration of drugs and, hence, side effects. In this review, we revise with a critical view the different families of nanoparticles and approaches followed so far with this aim., This work was supported by grant RTI2018-098027-B-C21, RTI2018-098027-B-C22, and PID2020-113058GB-I00 funded by MCIN/AEI/10.13039/501100011033, by ERDF A way of making Europe and by PI21/00181 from the Instituto Carlos III. This work was also supported by “Metalfármacos multifuncionales para el diagnóstico y la terapia”, through grant RED2018-102471-T, funded by MCIN/AEI/10.13039/501100011033. The ICN2 and IDIBELL are funded by the CERCA programme/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, grant SEV-2017-0706, funded by MCIN/AEI/10.13039/501100011033. COST is kindly acknowledged for stimulating scientific discussion and financial support via the Cost Action CA 17140 “Cancer nanomedicine from the bench to the bedside”. A.P.C. received funding from the ATTRACT project funded by the EC under Grant Agreement 777222. This work was also supported by the Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN [http://www.ciber-bbn.es/en], CB06/01/0010), an initiative of the Instituto de Salud Carlos III (Spain). The PhD program of X.M. was supported by the La Caixa-Severo Ochoa International PhD Fellowship.